3SBio's SSGJ-611: after 707, how to play the IL-4Rα card

On July 24, 2025, Pfizer and 3SBio completed the SSGJ-707 global licensing deal: US$1.25 billion upfront, US$4.8 billion in milestones, double-digit royalties, plus a US$100 million equity investment. It is one of the heaviest single-asset out-licensing deals in the history of Chinese biopharma BD. That night took 3SBio from a twin-engine company of "legacy biologics + Mandi" to, for the first time, a seat at the high end of the globalization table.

But 707 is not the end point. Pfizer took all rights to 707 outside China; what remains with 3SBio is China rights, double-digit royalties, plus the cash that followed. This means the company has nearly RMB 9 billion more ammunition on its books — and the most direct answer, at this moment in 2026, to where that ammunition should be aimed is SSGJ-611.

611 is not first-in-class. It is China's third domestic IL-4Rα antibody, with exactly the same pathway and mechanism as the already-marketed Dupixent and Keymed's stapokibart. On what basis can a fast-follower asset take on the role of "3SBio's second big globalization card"?

The answer lies in 3SBio's particular positioning: a 2,653-person sales force, coverage of 3,000+ tertiary hospitals, an autoimmune antibody portfolio (Yisaipu TNFα + an IL-17A antibody of the secukinumab class + 611 IL-4Rα) about to be complete, and its dermatology OTC flagship Mandi bringing built-in DTC reach. This is a first-tier Chinese commercial platform. On this platform, the road of "fast follower + strong commercial execution + overseas regional licensing" happens to be the most economical way for this type of large pharma to globalize.

This article uses ten thousand characters to unpack 611's strategic picture across seven dimensions — asset, clinical, registration, commercial, CMC, portfolio and BD — and the biggest question carried over from the 707 model: should 3SBio play the overseas card itself, or sell it again?

2.1 3SBio's real coordinates

The combination of 3SBio (HK: 1530) + Sunshine Guojian (STAR Market: 688336) is a rare "traditional biologics + innovative antibodies" dual-track listed structure in China. In 2024 group revenue was RMB 9.108 billion, up 16.5%; in 2025 it exceeded RMB 17.7 billion (including RMB 9 billion of one-off revenue from the 707 upfront), with net profit attributable to shareholders rising sharply. Market capitalization was re-rated to around US$7 billion after the 707 deal closed.

What really determines 611's strategic room is not these aggregate numbers but the portfolio structure:

• Nephrology / hematology line (TPIAO, EPIAO): a 20-year cash flow engine — the exclusive thrombopoietin and recombinant human erythropoietin have long funded R&D spending.
• Autoimmune line (Yisaipu, IL-17A antibody of the secukinumab class): Yisaipu launched in 2005 as China's first TNFα inhibitor; the IL-17A antibody was newly approved in February 2026 for psoriasis / ankylosing spondylitis; once 611 launches, they form an "autoimmune antibody trio" of TNF + IL-17A + IL-4Rα.
• Dermatology OTC line (Mandi): China's No. 1 OTC minoxidil brand, with complete internet hospital + DTC + e-commerce channels, covering aesthetic dermatology clinics and self-pay consumers — the key differentiated channel separating 611 from other purely prescription biotech assets.
• Oncology line (Cipterbin): a trastuzumab-class product, providing accumulated large-molecule CMC and commercialization experience.

On the sales side, 2,653 frontline sales reps plus 1,248 distributors and 1,811 third-party promotion partners form a coverage network of 3,000+ tertiary hospitals + 9,000+ secondary and lower hospitals. This is the physical boundary of a first-tier Chinese commercial platform.

2.2 What kind of molecule is SSGJ-611

SSGJ-611 is a humanized IgG4 monoclonal antibody developed in-house by Sunshine Guojian, targeting the IL-4 receptor α chain; its mechanism is exactly the same as Sanofi/Regeneron's Dupixent (dupilumab) and Keymed's CM310 (stapokibart, the first domestic product in the class): by blocking IL-4Rα, it simultaneously inhibits both the IL-4 and IL-13 type 2 inflammatory pathways.

It is neither in-licensed nor a platform collaboration; it is entirely Sunshine Guojian's own work from molecular design to process validation. This means all overseas rights, all IP and all future BD bargaining chips are in the company's own hands — crucial for any overseas licensing negotiation later on.

The indication layout fully replicates Dupixent's approach of rolling out across the full type 2 spectrum:

Four China indications are advancing in parallel, covering four department entry points: dermatology, ENT, respiratory and pediatrics. If realized, this layout would be an almost complete Chinese replica of Dupixent — but standing ahead is Keymed's stapokibart, which launched a year and a half earlier, and following behind are at least four domestic IL-4Rα products in Phase 3.

3.1 Phase 2 data review

The key Phase 2 data read out so far come from NCT05544591, with 93 patients at 23 centers in China:

• Primary endpoint EASI-75: 611 Q2W 60.0%, Q4W 48.8%, placebo 15.6% (all p<0.01).
• Secondary endpoint IGA 0/1: 611 pooled 35.5%, placebo 9.4%.
• Safety: the most common adverse reaction was upper respiratory tract infection, similar to placebo; no new signals.

Taken alone, these numbers broadly line up with Dupixent's Phase 2 data from the same stage. But the claim management has repeatedly stressed in investor communications — "efficacy superior to Dupixent, supporting Q4W long-acting maintenance" — remains at the level of indirect comparison, without head-to-head support. At the BD negotiating table, in FDA Type B meetings and at the NRDL negotiating table alike, this point will be challenged again and again.

3.2 The real gap to global / Chinese benchmarks

In AD, 611 is expected to be China's third domestic launch, 1–1.5 years behind stapokibart. Hoping to win back share through structural differentiation of the molecule is almost unrealistic — same pathway, same mechanism, same safety profile. Only four real points of difference can be established: (1) if a Q4W long-acting maintenance label can be written into the prescribing information, it creates a substantive difference in adherence and outpatient use; (2) COPD is the only indication in China where 611 does not trail stapokibart, being the first domestic product in Phase 3; (3) pediatric AD progress is in the domestic first tier; (4) the speed of coverage brought by 3SBio's commercial platform.

The AD NDA was formally accepted by CDE in February 2026. This is a relatively clear registration path: an independent Chinese Phase 2 + 3 data package, against placebo + standard topical therapy, with no bridging and no MRCT. From pre-meeting communication after Phase 2 to pre-pivotal communication for Phase 3, the rhythm of dialogue within the CDE system is mature. The advantage of this path is predictability of review; the disadvantage is that this data package is hard to extrapolate to FDA and EMA.

The door to expedited review is essentially shut. Breakthrough Therapy and priority review usually require "seriously life-threatening with no effective treatment" — in AD, two approved biologics, Dupixent and stapokibart, already stand in front, so 611 cannot meet this threshold. The global first IL-4Rα label in COPD belongs only to Dupixent; 611 is China's second Phase 3 asset but can still seek conditional approval, and this is the indication truly worth applying for acceleration.

In terms of timing, the most critical expected windows for 611's China launches are:

• AD approval: 2026 H2 – 2027 Q1 (standard review cycle);
• CRSwNP approval: 2027–2028;
• COPD approval: 2028–2029, first domestic IL-4Rα in COPD;
• Pediatric AD: follow-on in 2027–2028.

This timetable means that in the year 611 launches in AD, it will face stapokibart in its second year on the NRDL, the cognitive foundation Dupixent has built among dermatology KOLs over five years, and the countdown to entry of later domestic peers. The "first wave in China" window has been lost; whether it can win the position of "China's mainstay" depends on whether the commercial platform in the next chapter can get running.

This section is where 611 really wins or loses. For a biologic taking the fast-follower route and launching 1.5 years after the first mover, the only lever that can win back market share is the commercial platform. How much 3SBio can amplify it is broken down across four dimensions.

5.1 The hard strength of the sales force and hospital network

3SBio group has 2,653 frontline sales reps; adding distributors and third-party promotion partners gives a total of more than 5,700 commercial touchpoints. It covers 3,000+ tertiary hospitals and 9,000+ secondary and lower hospitals. At this scale, only a few domestic innovative biopharma companies such as Hengrui, Sino Biopharm and CSPC can match it; Keymed, Genrix Bio and Mabgeek, which compete directly with 611 in the same period, have sales teams ranging from about a hundred to a few hundred people.

The key coverage point is that 3SBio already "has people" in all four target departments: dermatology through years of Mandi, ENT / respiratory through the long-standing extension of Yisaipu's rheumatology team, and pediatrics through partial spillover from Cipterbin's oncology support network. In other words, on the day 611 launches, 3SBio barely needs to hire a single sales rep from scratch.

5.2 The synergy structure of the autoimmune antibody trio

This is the key to 611 being more than a "single product". 3SBio's IL-17A antibody, newly approved in February 2026, targets psoriasis and ankylosing spondylitis; the TNFα inhibitor Yisaipu targets rheumatoid arthritis and psoriasis; 611 IL-4Rα targets AD, CRSwNP and COPD. Three pathways and three sets of indications, promoted by the same sales team, to the same KOLs and in front of the same hospital formulary committees.

This structure is very rare among Chinese innovative biopharma companies. Its direct significance is not adding up sales, but "dividing down access friction" — having one hospital's formulary committee evaluate two new drugs, IL-17A + IL-4Rα, at once is far easier than two companies knocking on the door separately; the cost of one group of dermatology KOLs maintaining three products at once is far lower than three companies each maintaining their own.

5.3 The unique value of Mandi's DTC

Mandi is one of 3SBio's most underrated assets. China's No. 1 OTC minoxidil brand, it deeply operates three channels: aesthetic dermatology clinics, internet hospitals and e-commerce. The path from consumer awareness to purchase is already mature. The significance of this channel for 611 lies not within the NRDL but outside it — a considerable share of patients with moderate-to-severe AD are willing to pay out of pocket for biologics to avoid the safety concerns of long-term steroids and JAK inhibitors. Mandi's DTC reach converts directly into early patient acquisition and ongoing conversion in 611's self-pay market.

This is an advantage few Chinese biopharma companies can get: owning a dermatology consumer channel that has genuinely operated DTC and internet hospitals. The expected target is a self-pay share of 15–25% within 12 months of launch — if this is achieved, it will become 611's real economic moat.

5.4 After prices are compressed, how to make up with volume

This is the harshest side of the commercial platform logic. Dupixent's annual treatment cost in China has already been pushed down to RMB 15,000, and stapokibart's price has been anchored in the same band after entering the NRDL in 2025; when 611 enters NRDL negotiations in 2026 or 2027 it will have almost no room for a premium, with an expected annual treatment cost in the RMB 12,000–18,000 range and a first-negotiation price cut of 50–65% a reasonable expectation.

This kind of price compression is fatal for a pure biotech — single-product gross margin is flattened with no portfolio to dilute costs; but for a company like 3SBio that has manufactured its own biologics for 20 years with a mature CMC cost structure, it is a structural advantage. COGS is expected to be around 10% of the selling price, and even with aggressive NRDL price cuts, operating gross margin can stay above 80%. This is the real watershed between 3SBio and peers such as Keymed, Genrix Bio and Mabgeek in long-term return models.

On CMC, the domestic market is essentially worry-free. Sunshine Guojian has four biologics bases in Shenyang, Shenzhen, Shanghai and Hangzhou, and Yisaipu has been supplied continuously for 20 years since its 2005 launch with no record of interruption. NDA acceptance itself means comparability, stability and scale-up validation between the commercial and clinical processes have passed CDE's acceptance threshold. The same molecule shares one commercial process across AD / CRSwNP / COPD / pediatric AD, with no need to redo CMC for new indications.

The problem is overseas. 3SBio has no manufacturing base of its own in the US or Europe, no record of passing an FDA Pre-Approval Inspection, and no real-world experience of EMA on-site inspections. Dupixent and Yisaipu are not in the same registration system, so past CMC credibility cannot transfer. This means that if 611 goes the overseas licensing route, the overseas CMC dossier must be ready 12–18 months before BD starts, with process transfer or shared-line manufacturing plans arranged for potential partners. Otherwise, during due diligence, the overseas CMC gap will directly become a deduction that lowers valuation.

Another hidden CMC issue is dosage form innovation. Dupixent has already launched an auto-injector pen and high-concentration formulations to meet adherence needs for long-term use. 611's publicly disclosed dosage form only goes as far as a prefilled syringe; an auto-injector pen and low-dose pediatric strengths have not been disclosed. If 611 wants to truly land its Q4W maintenance differentiation claim, an auto-injector pen must launch in the 2027–2029 window. Otherwise, so-called "long-acting convenience" is only an advantage in clinical data, and cannot turn into patient preference in use.

In 3SBio's 2025 portfolio structure, 611 and 707 stand side by side as the two flagship assets. But their roles are completely different.

707 is a global option that has already realized part of its value. With Pfizer taking over overseas development, the company's R&D burden has been significantly reduced, and overseas sales milestones and double-digit royalties become cash flow realized over the next 5–10 years. What 707 provides the company is a valuation anchor and an overseas credibility asset — proof that 3SBio can sell a domestic innovative drug into the top valuation range of global big pharma.

611 is the main cash flow engine in the Chinese market. Over the three years 2026–2028, as AD launches and scales, CRSwNP / COPD indications take over in turn and NRDL coverage expands, 611's China sales curve will become the first support of 3SBio's innovative drug line. It does not need overseas royalties to support its valuation; what it needs to support is the company proving to capital markets that the road of "innovative drug commercialization + platform leverage" genuinely works.

Next-generation molecules (IL-5, TSLP, OX40, etc.) are the global differentiation spare parts for 2028+. These molecules may take a completely different route — first-in-class pace + independent going global — leveraging the cash ammunition and team experience accumulated from the 707 deal and 611's commercial platform.

This "three-part division of labor" has a hidden constraint: 611 should not compete for overseas self-development resources. 3SBio's overseas team, overseas clinical operations experience and overseas registration capabilities are all starting from almost zero — 707 was solved by leaning on Pfizer, and taking the same road for 611 is most economical. Keep money, people and attention for the 2028+ next-generation molecules to run the real "independent globalization" experiment, while 611 overseas only plays the role of "regional licensing + cash in hand". This is the optimal allocation at the portfolio level.

The path to maximizing 611's overseas value is the question in this analysis with the most room for debate. Three options are on the table:

Option A: fully replicate the 707 model

License all overseas rights, split by region, to MNCs, with 3SBio retaining exclusive self-commercialization in China. Priority targets are large pharma with dual dermatology/respiratory commercial capability (Sanofi/Regeneron excluded because of conflict of interest; candidates include Pfizer, AbbVie, Eli Lilly, J&J, etc.). Target deal structure: US$300–500 million upfront + US$1–2 billion in milestones + double-digit royalties + a co-development option (COPD indication).

This is the reasonable expectation in the base case. 611's BD valuation ceiling is limited by the reality that "the target is already occupied by Dupixent", so the upper limit of a single deal's upfront is unlikely to reach 707's scarcity premium. But with regional splits into multiple deals plus full retention of self-commercialized China rights, overall value can still reach the US$1.5–3 billion range.

Option B: go global independently (not recommended)

3SBio builds its own US or European subsidiary, launches its own Phase 3 and self-commercializes. The resource consumption of this road is at the RMB 1 billion+ level, with a 3–5-year time window. But the overseas IL-4Rα market has already been fully educated by Dupixent and the window abroad has not truly opened; the ROI of going global independently is far lower than redirecting resources to next-generation molecules. This road only suits scarce first-in-class assets, not a fast follower like 611.

Option C: wait + data-driven licensing

Don't rush into BD around NDA approval; instead spend 1–2 years accumulating large-scale Chinese commercial data + real-world evidence, then negotiate overseas. The logic is to use real-world data to make up for the lack of head-to-head studies and increase bargaining power. The risk of this road is that the window is squeezed by competitors — if Keymed's stapokibart completes ex-China BD first during 2026–2027, 611's overseas bargaining power would be significantly reduced.

8.4 The optimal window for BD timing

Overall judgment: 611's main BD window is 2026 H2 – 2027 H1, i.e. around approval of the China AD NDA and as CRSwNP / COPD Phase 3 data read out. In this window, upward valuation (China registration value realized + improved visibility of indication expansion) and external pressure (Keymed's overseas moves + competition from global peers) are stacked at the same time, making it the peak of bargaining power at the BD table.

It is recommended that 3SBio immediately form a dedicated BD project team, have the data room, overseas CMC package and IP due diligence materials ready in 2026 H1, start contact with potential partners in 2026 H2, and announce the first regional deal in 2027 H1. A secondary window can be kept open until after the 2027 NRDL round, using post-launch Chinese real-world data to negotiate the remaining territories (Europe, emerging markets, Japan).

611 will not become 3SBio's "jewel in the crown" — that position has been taken by 707. But 611 may become 3SBio's most important pillar: in the Chinese market it has to prove that the combination of "commercial platform + autoimmune antibody trio + Mandi DTC" is enough to take on a same-class product that launched a year and a half earlier; at the overseas licensing table it has to prove that 3SBio can repeatedly replicate the 707 model; and at the portfolio level it has to take on the role of China's main cash flow engine in 2026–2028, turning the RMB 9 billion of ammunition on the books, Pfizer royalties and autoimmune portfolio sales into globalization capital for next-generation molecules.

Among Chinese biopharma companies in 2026, no more than five have all four at once: "a big out-licensing deal done + a domestically differentiated second-tier asset + a complete local commercial platform + overseas credibility". With the 611 card alone, 3SBio is unlikely to change the landscape of the global IL-4Rα market; but it can change the company's position in China's innovative drug valuation system — from "707's moment in the sun" to "a sustainably replicable globalization paradigm".

That is 611's real strategic significance. And it is why, beyond the halo of 707, the company must push 611 hard.